[go: up one dir, main page]

WO2005084205A3 - Diamino thiazoloindan derivatives and their use - Google Patents

Diamino thiazoloindan derivatives and their use Download PDF

Info

Publication number
WO2005084205A3
WO2005084205A3 PCT/US2005/005921 US2005005921W WO2005084205A3 WO 2005084205 A3 WO2005084205 A3 WO 2005084205A3 US 2005005921 W US2005005921 W US 2005005921W WO 2005084205 A3 WO2005084205 A3 WO 2005084205A3
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
aralkyl
alkynyl
ring
line drawn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/005921
Other languages
French (fr)
Other versions
WO2005084205A2 (en
Inventor
Jeffrey Sterling
Liat Hayardeny-Nisimov
David Lerner
Yaacov Herzig
Eliezer Falb
Gyorgy Toth
Sandor Molnar
Dalia Pinkert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Original Assignee
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd, Teva Pharmaceuticals USA Inc filed Critical Teva Pharmaceutical Industries Ltd
Publication of WO2005084205A2 publication Critical patent/WO2005084205A2/en
Publication of WO2005084205A3 publication Critical patent/WO2005084205A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/57—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems of the carbon skeleton
    • C07C211/60—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems of the carbon skeleton containing a ring other than a six-membered aromatic ring forming part of at least one of the condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C07C233/14—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/41—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The subject invention provides a compound having the structure: wherein Y is O, NR3R4 or NOR6; R3 is H, alkyl, aralkyl, alkynyl, trifluoroacetyl, t-butoxycarbonyl or an acyl group; R4 is H, alkyl, aralkyl, or alkynyl; R6 is H or C1-C4 alkyl; R1and R2 are each independently H, alkyl, aralkyl, or alkynyl; the curved line drawn from S to the center of the phenyl ring and the straight line drawn from N to the center of the ring indicate that S and N are part of a 5 membered ring which shares two carbons with the phenyl ring; and the dashed line drawn from the carbon atom on the cyclopentyl ring to Y represents a bond when Y is O or NOR6 and is absent when Y is NR3R4 and wherein wherein X is H or O; and R5 is H, alkyl, trifluoroacetyl, t-butoxycarbonyl or an acyl group, or an enantiomer, or a tautomer, or a pharmaceutically acceptable salt thereof, a process for preparing the compounds and a method of treating Parknison’s disease, multiple sclerosis or depression with the compounds of the invention.
PCT/US2005/005921 2004-02-27 2005-02-25 Diamino thiazoloindan derivatives and their use Ceased WO2005084205A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78942104A 2004-02-27 2004-02-27
US10/789,421 2004-02-27

Publications (2)

Publication Number Publication Date
WO2005084205A2 WO2005084205A2 (en) 2005-09-15
WO2005084205A3 true WO2005084205A3 (en) 2005-10-20

Family

ID=34919709

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/005921 Ceased WO2005084205A2 (en) 2004-02-27 2005-02-25 Diamino thiazoloindan derivatives and their use

Country Status (1)

Country Link
WO (1) WO2005084205A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101300006B (en) * 2005-06-02 2012-07-25 叶林发现公司 MAO-B inhibitors useful for treating obesity
SA109300120B1 (en) * 2008-02-21 2011-10-08 استرازينيكا ايه بي Compound (R) -N*6*-Ethyl-6, 7-Dihydro-5H-Indeno (5,6- D) Thiazole-2, 6-Diamine and the Use as Antipsychotics
BR112013001350A2 (en) * 2010-07-19 2016-05-17 Onyx Pharma Inc cyclopentaquinazoline synthesis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291494B1 (en) * 1998-07-01 2001-09-18 Wikstroem Haakan Vilhelm 2-aminothiazol-fused 2-aminoindans and 2-aminotetralins and their use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291494B1 (en) * 1998-07-01 2001-09-18 Wikstroem Haakan Vilhelm 2-aminothiazol-fused 2-aminoindans and 2-aminotetralins and their use

Also Published As

Publication number Publication date
WO2005084205A2 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
TW200508180A (en) Therapeutic agents
EP4467549A3 (en) Intermediates of n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
MX2007007220A (en) Pyrazolone compounds as metabotropic glutamate receptor agonists for the treatment of neurological and psychiatric disorders.
WO2004087699A3 (en) Thiazoles useful as inhibitors of protein kinases
WO2004087698A3 (en) Thiazoles useful as inhibitors of protein kinases
WO2004013120A8 (en) Novel benzodioxoles
SE0104334D0 (en) Therapeutic agents
MY156747A (en) Isoxazolo-pyridine derivatives
MXPA05009359A (en) 2,5- and 2,6-substituted tetrahydroisoquinolines for use as 5-ht6 modulators.
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
ATE457988T1 (en) A2A ADENOSINE RECEPTOR ANTAGONISTS
PT1159279E (en) 4-OXO-4,7-DIHYDROTIENE-2,3-B | PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS
CA2279620A1 (en) 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands (d4)
IL160045A0 (en) Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
WO2007062999A3 (en) 1,5-substituted indol-2-yl amide derivatives
JP2005511697A5 (en)
HUP0400743A2 (en) Imidazo[1,5-a]pyrimido[5,4-d]benzazepine derivatives, process for their preparation and pharmaceutical conpositions containing them
PH12021552533A1 (en) Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease
MX2023006842A (en) Manufacturing process and intermediates for a pyrrolo[2,3- d]pyrimidine compound and use thereof.
AU6517598A (en) 4-tetrahydropyridylpyrimidine derivative
WO2007100583A3 (en) Propargylated aminoindans, processes for preparation, and uses thereof
AU2006294633A8 (en) 7-[2-[4- (6-fluoro-3-methyl -1,2-benzisoxazol-5-yl) -1-piperazinyl]ethyl] -2- ( 1-propynyl) -7h-pyrazolo- [ 4,3-e]-[1,2,4] -triazolo- [1,5-c] -pyrimidin- 5 amine
MXPA05005790A (en) Aminoalkoxyindoles as 5-ht6-receptor ligands for the treatment of cns-disorders.
WO2005084205A3 (en) Diamino thiazoloindan derivatives and their use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase